Abstract:Background: The mortality rate of liver cancer ranks third in the world, and hepatocellular carcinoma (HCC) is a malignant tumor of the digestive tract. Cucurbitacin B (CuB), a natural compound extracted from Cucurbitaceae spp., is the main active component of Chinese patent medicine the Cucurbitacin Tablet, which has been widely used in the treatment of various malignant tumors in clinics, especially HCC. Purpose: This study explored the role and mechanism of CuB in the suppression of liver cancer progression. Methods: Cell Counting Kit -8 (CCK-8) and colony formation assays were used to detect the inhibitory function of CuB in Huh7, Hep3B, and Hepa1/6 hepatoma cells. Calcein-AM/propidium iodide (PI) staining and lactate dehydrogenase (LDH) measurement assays were performed to determine cell death. Mitochondrial membrane potential (Delta psi m) was measured, and flow cytometry was performed to evaluate cell apoptosis and cell cycle. Several techniques, such as proteomics, Western blotting (WB), and ribonucleic acid (RNA) interference, were utilized to explore the potential mechanism. The animal experiment was performed to verify the results of in vitro experiments. Results: CuB significantly inhibited the growth of Huh7, Hep3B, and Hepa1/6 cells and triggered the cell cycle arrest in G2/M phage without leading to cell death, especially apoptosis. Knockdown of insulin -like growth factor 2 mRNA-binding protein 1 (IGF2BP1), a target of CuB, did not reverse CuB elicited cell cycle arrest. CuB enhanced phosphorylated ataxia telangiectasia mutated (p -ATM) and phosphorylated H2A histone family member X (gamma-H2AX) levels. Moreover, CuB increased p53 and p21 levels and decreased cyclin-dependent kinase 1 (CDK1) expression, accompanied by improving phosphorylated checkpoint kinase 1 (p-CHK1) level and suppressing cell division cycle 25C (CDC25C) protein level. Interestingly, these phenomena were partly abolished by a deoxyribonucleic acid (DNA) protector methylproamine (MPA). Animal studies showed that CuB also significantly suppressed tumor growth in BALB/c mice bearing Hepa1/6 cells. In tumor tissues, CuB reduced the expression levels of proliferating cell nuclear antigen (PCNA) and gamma-H2AX but did not change the terminal deoxynucleotidyl transferase deoxyuridine triphosphate (dUTP) nick -end labeling (TUNEL) level. Conclusion: This study demonstrated for the first time that CuB could effectively impede HCC progression by inducing DNA damage -dependent cell cycle arrest without directly triggering cell death, such as necrosis and apoptosis. The effect was achieved through ataxia telangiectasia mutated (ATM) -dependent p53-p21-CDK1 and checkpoint kinase 1 (CHK1)-CDC25C signaling pathways. These findings indicate that CuB may be used as an anti-HCC drug, when the current findings are confirmed by independent studies and after many more clinical phase 1, 2, 3, and 4 testings have been done.

Anti-hepatoma effects of cucurbitacin B combined with different herb components in vitro

In Vitro and in Vivo Antitumor Activity of Cucurbitacin C, a Novel Natural Product from Cucumber

Inhibitory Effect of Cucurbitacin E on the Proliferation of Breast Cancer Cells and Its Mechanism

Growth inhibitory effect of Cucurbitacin E on breast cancer cells.

Global Metabolomic and Lipidomic Analysis Reveal the Synergistic Effect of Bufalin in Combination with Cinobufagin Against HepG2 Cells.

Synthesis of Cucurbitacin B Derivatives As Potential Anti-Hepatocellular Carcinoma Agents

Design, Synthesis, and Antitumor Evaluation of Novel Mono-Carbonyl Curcumin Analogs in Hepatocellular Carcinoma Cell

Total cucurbitacins from Herpetospermum pedunculosum pericarp do better than Hu-lu-su-pian (HLSP) in its safety and hepatoprotective efficacy

Cucurbitacin B Suppresses Hepatocellular Carcinoma Progression Through Inducing DNA Damage-Dependent Cell Cycle Arrest.

Cucurbitacin I exerts its anticancer effects by inducing cell cycle arrest via the KAT2a-ube2C/E2F1 pathway and inhibiting HepG2-induced macrophage M2 polarization

In Vitro and in Vivo Evaluation of Cucurbitacin E on Rat Hepatic CYP2C11 Expression and Activity Using LC-MS/MS

The Antiproliferative and Proapoptotic Effects of Cucurbitacin B on BPH-1 Cells via the p53/MDM2 Axis

Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics

A combination index and glycoproteomics-based approach revealed synergistic anticancer effects of curcuminoids of turmeric against prostate cancer PC3 cells

Antiproliferative Effect of a Novel Cationic Nanocurcumin on Human Hepatocellular Carcinoma of HepG2 Cells.

Metabolic fate of the natural anticancer agent cucurbitacin B: an LC-MS/MS-enabled profiling of its major phase I and II conjugates in vivo

Anti-proliferative Effects of Curcumin on Human Hepatocellular Carcinoma HepG2 and Bel-7404 Cells

Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma

Inhibitory effect of harmine derivative B-9-3 combined with five traditional anti-tumor drugs on cancer cells in vitro

Synergistic Effects of Curcumin with Emodin Against the Proliferation and Invasion of Breast Cancer Cells Through Upregulation of Mir-34A

Comprehensive Assessment of Cucurbitacin E Related Hepatotoxicity and Drug-Drug Interactions Involving CYP3A and P-glycoprotein.